CN101357215B - Medicine combination for treating viral hepatitis and quality control method thereof - Google Patents

Medicine combination for treating viral hepatitis and quality control method thereof Download PDF

Info

Publication number
CN101357215B
CN101357215B CN 200710119920 CN200710119920A CN101357215B CN 101357215 B CN101357215 B CN 101357215B CN 200710119920 CN200710119920 CN 200710119920 CN 200710119920 A CN200710119920 A CN 200710119920A CN 101357215 B CN101357215 B CN 101357215B
Authority
CN
China
Prior art keywords
weight portion
herba
solution
radix
weight portions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN 200710119920
Other languages
Chinese (zh)
Other versions
CN101357215A (en
Inventor
付立家
付建家
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Asia East Bio Pharmaceutical Co Ltd
Original Assignee
Beijing Asia East Bio Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Asia East Bio Pharmaceutical Co Ltd filed Critical Beijing Asia East Bio Pharmaceutical Co Ltd
Priority to CN 200710119920 priority Critical patent/CN101357215B/en
Publication of CN101357215A publication Critical patent/CN101357215A/en
Application granted granted Critical
Publication of CN101357215B publication Critical patent/CN101357215B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a pharmaceutical composition used for treating virus hepatitis, a preparation method and a quality control method thereof. The pharmaceutical composition has the raw materials of herba artemisiae capillaris, radix isatidis, rhizoma dryopteris crassirhizomae, indian bread, radix curcumae, herba scutellariae barbatae and patchouli, etc. The quality control method is that the traditional Chinese medicine provided by the invention is obtained by a great deal of creative experiments and screening as well as by the screening for a sample treatment method and the selection to a developing agent in a distinguishing method, and the distinguishing specificity is good; furthermore, the methods are economical and applicable, has rapid result and can be applied to different thin-layer plates. In a content measuring method, by the screening for a processing method of samples and test product and the selection to the developing agent, the content measuring method can effectively carry out quality control on products; furthermore, compared with other methods, the product measured by the method has more stable drug effect.

Description

A kind of pharmaceutical composition and method of quality control for the treatment of viral hepatitis
Invention field
The present invention relates to a kind of pharmaceutical composition and preparation method and method of quality control, particularly a kind of pharmaceutical composition and preparation method and method of quality control for the treatment of viral hepatitis.
Background technology
Viral hepatitis is the common transmittable disease that is caused by multiple hepatitis virus, has that infectiousness is strong, the route of transmission is complicated, popular wide general, and sickness rate is than characteristics such as height.Mainly show as weak, loss of appetite clinically, feel sick, vomiting, hepatomegaly and liver function injury, part patient can have jaundice and heating.Urticaria, arthralgia or upper airway symptoms appear in some patient, severe patient even can develop into liver cirrhosis even hepatocarcinoma, the serious harm human health.Though at present the medicine of used clinically treatment viral hepatitis has certain curative effect, exist to some extent body to be developed immunity to drugs and defective such as addiction, side effect be obvious.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition; Another purpose of the present invention is to provide a kind of pharmaceutical composition for the treatment of viral hepatitis; The 3rd purpose of the present invention is to provide this preparation of drug combination method; The 4th purpose of the present invention is to provide the method for quality control of this pharmaceutical composition.
The present invention seeks to 1,2 to realize by following technical solution:
Technical scheme 1:
The crude drug of pharmaceutical composition of the present invention consists of:
Poria 500-1500 weight portion, Herba Artemisiae Scopariae 500-1500 weight portion, Rhizoma Atractylodis Macrocephalae 500-1500 weight portion, Radix Curcumae 150-450 weight portion, Radix Angelicae Sinensis 250-750 weight portion, succinum 50-150 weight portion, the Radix Paeoniae Alba (stir-fry) 500-1500 weight portion, Herba Scutellariae Barbatae 500-1500 weight portion, Fructus Amomi 100-300 weight portion, Rhizoma Polygoni Cuspidati 250-750 weight portion, Radix Salviae Miltiorrhizae 500-1500 weight portion, Herba Lycopi 250-750 weight portion, Radix Bupleuri 150-450 weight portion, Herba Pogostemonis 150-450 weight portion, Herba Eupatorii 250-750 weight portion, Flos Carthami 150-450 weight portion.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Poria 960 weight portions, Herba Artemisiae Scopariae 960 weight portions, the Rhizoma Atractylodis Macrocephalae 960 weight portions, Radix Curcumae 320 weight portions, Radix Angelicae Sinensis 480 weight portions, succinum 96 weight portions, the Radix Paeoniae Alba (stir-fry) 960 weight portions, Herba Scutellariae Barbatae 960 weight portions, Fructus Amomi 192 weight portions, Rhizoma Polygoni Cuspidati 480 weight portions, Radix Salviae Miltiorrhizae 960 weight portions, Herba Lycopi's 480 weight portions, Radix Bupleuri 320 weight portions, Herba Pogostemonis 320 weight portions, Herba Eupatorii 480 weight portions, Flos Carthami 320 weight portions.
Technical scheme 2:
The crude drug of pharmaceutical composition of the present invention consists of:
Poria 500-1500 weight portion, Herba Artemisiae Scopariae 500-1500 weight portion, Radix Curcumae 150-450 weight portion, Radix Angelicae Sinensis 250-750 weight portion, succinum 50-150 weight portion, the Radix Paeoniae Alba (stir-fry) 500-1500 weight portion, Herba Scutellariae Barbatae 500-1500 weight portion, Fructus Amomi 100-300 weight portion, Rhizoma Polygoni Cuspidati 250-750 weight portion, Radix Salviae Miltiorrhizae 500-1500 weight portion, Herba Lycopi 250-750 weight portion, Radix Bupleuri 150-450 weight portion, Herba Pogostemonis 150-450 weight portion, Herba Eupatorii 250-750 weight portion, Flos Carthami 150-450 weight portion, Radix Isatidis 500-1500 weight portion, Rhizoma Dryopteris Crassirhizomatis 250-750 weight portion, Herba Hedyotidis Diffusae 500-1500 weight portion, Rhizoma Paridis 250-750 weight portion.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Poria 960 weight portions, Herba Artemisiae Scopariae 960 weight portions, Radix Curcumae 320 weight portions, Radix Angelicae Sinensis 480 weight portions, succinum 96 weight portions, the Radix Paeoniae Alba (stir-fry) 960 weight portions, Herba Scutellariae Barbatae 960 weight portions, Fructus Amomi 192 weight portions, Rhizoma Polygoni Cuspidati 480 weight portions, Radix Salviae Miltiorrhizae 960 weight portions, Herba Lycopi's 480 weight portions, Radix Bupleuri 320 weight portions, Herba Pogostemonis 320 weight portions, Herba Eupatorii 480 weight portions, Flos Carthami 320 weight portions, Radix Isatidis 960 weight portions, Rhizoma Dryopteris Crassirhizomatis 480 weight portions, Herba Hedyotidis Diffusae 960 weight portions, Rhizoma Paridis 480 weight portions.
Get the pharmaceutical composition crude drug of technical solution of the present invention 1,2, add conventional adjuvant, according to common process, make the dosage form of clinical acceptance, include but not limited to mixture, concentrated pill, capsule, drop pill, granule, tablet, soft capsule, slow releasing agent, oral liquid.
Pharmaceutical composition technical scheme 1 preparation mixture method of the present invention is: Radix Angelicae Sinensis, Radix Curcumae, Herba Pogostemonis, Herba Eupatorii, Fructus Amomi, Herba Lycopi extracted volatile oil 6-10 hour, and the aqueous solution after distillation device is in addition collected; Volatile oil is with the beta-schardinger dextrin-saturated water solution method inclusion of 3-5 times of weight portion, drying, the volatile oil beta-cyclodextrin inclusion complex, standby; Radix Salviae Miltiorrhizae is with 85% alcohol reflux of 4-8 times of weight portion 1-3 time, and each 0.5-1.5 hour, merge extractive liquid, filtered, and filtrate recycling ethanol is not to there being the alcohol flavor, Radix Salviae Miltiorrhizae extract, standby; Medicinal residues and all the other flavour of a drug decoct with water 1-3 time, and the decocting that at every turn adds 6-10 times of weight portion boiled 1-2 hour, and collecting decoction filters; Aqueous solution after filtrate and the above-mentioned distillation merges, be concentrated into 60~65 ℃ of relative densities and be 1.02~1.04 thick paste I, add ethanol and make and contain alcohol amount and reach 60-80%, left standstill 12-36 hour, filter, filtrate recycling ethanol is to an amount of, merge with above-mentioned Radix Salviae Miltiorrhizae extract, and the thick paste II that to be concentrated into 60~65 ℃ of relative densities be 1.10-1.15, add 80% simple syrup 900-1200 parts by volume, the volatile oil beta-cyclodextrin inclusion complex is ground into fine powder, adds in the extractum; Add sodium benzoate 9-10g again, stir evenly, add water to the 3000-4500 parts by volume, filter, fill, sterilization, promptly.
Pharmaceutical composition technical scheme 2 preparation methoies of the present invention are: above 19 flavors, and Radix Angelicae Sinensis, Radix Curcumae, Herba Pogostemonis, Herba Eupatorii, Fructus Amomi, Herba Lycopi extracted volatile oil 6-10 hour, and the aqueous solution after distillation device is in addition collected; Volatile oil is with the beta-schardinger dextrin-saturated water solution method inclusion of 3-5 times of weight portion, drying, the volatile oil beta-cyclodextrin inclusion complex, standby; Radix Salviae Miltiorrhizae is with 85% alcohol reflux of 4-8 times of weight portion 1-3 time, and each 0.5-1.5 hour, merge extractive liquid, filtered, and filtrate recycling ethanol is not to there being the alcohol flavor, Radix Salviae Miltiorrhizae extract, standby; 12 flavors such as medicinal residues and all the other Herba Artemisiae Scopariaes decoct with water 1-3 time, and the decocting that at every turn adds 6-10 times of weight portion boiled 1-2 hour, and collecting decoction filters; Aqueous solution after filtrate and the above-mentioned distillation merges, be concentrated into 60~65 ℃ of relative densities and be 1.02~1.04 thick paste I, adding ethanol makes the alcohol amount of containing reach 60-80%, left standstill 12-36 hour, filter, filtrate recycling ethanol is to an amount of, merge with above-mentioned Radix Salviae Miltiorrhizae extract, be concentrated into the thick paste II that relative density is 1.10-1.15, add the volatile oil beta-cyclodextrin inclusion complex and be ground into fine powder, add conventional adjuvant, according to common process, make the dosage form of clinical acceptance, include but not limited to mixture, concentrated pill, capsule, drop pill, granule, tablet, soft capsule, slow releasing agent, oral liquid or lyophilized injectable powder.
Pharmaceutical composition technical scheme 2 preparation mixture methods of the present invention are preferably: above 19 flavors, and Radix Angelicae Sinensis, Radix Curcumae, Herba Pogostemonis, Herba Eupatorii, Fructus Amomi, Herba Lycopi extracted volatile oil 8 hours, and the aqueous solution after distillation device is in addition collected; Volatile oil is with 40 ℃ of inclusions of beta-schardinger dextrin-saturated water solution method of 4 times of weight portions, 40 ℃ of dryings, the volatile oil beta-cyclodextrin inclusion complex, standby; Radix Salviae Miltiorrhizae is with 85% alcohol reflux of 6 times of weight portions 2 times, and each 1 hour, merge extractive liquid, filtered, and filtrate recycling ethanol is not to there being the alcohol flavor, Radix Salviae Miltiorrhizae extract, standby; 12 flavors such as medicinal residues and all the other Herba Artemisiae Scopariaes decoct with water 2 times, add 8 times of water gagings at every turn and decoct 1.5 hours, and collecting decoction filters; Aqueous solution after filtrate and the above-mentioned distillation merges, be concentrated into 60~65 ℃ of relative densities and be 1.02~1.04 thick paste I, add ethanol and make and contain alcohol amount and reach 70%, left standstill 24 hours, filter, filtrate recycling ethanol is to an amount of, merge with above-mentioned Radix Salviae Miltiorrhizae extract, and the thick paste II that to be concentrated into 60~65 ℃ of relative densities be 1.10-1.15, add 80% simple syrup 960 parts by volume, the volatile oil beta-cyclodextrin inclusion complex is ground into fine powder, adds in the extractum; Add sodium benzoate 9.6g again, add water to 3200 parts by volume, filter, fill, sterilization, promptly.
Pharmaceutical composition method of quality control of the present invention comprises one or more in following discrimination method and/or the assay:
Differentiate: A, get this drug combination preparation 1/100-3/100 day and use dosage, add water 10-30ml and make dissolving, with ethyl acetate extraction 1-3 time, 20-40ml for the first time, 10-30ml for the second time, combined ethyl acetate liquid, water bath method, residue adds ethyl acetate 0.5-1.5ml makes dissolving, as need testing solution; Other gets Herba Artemisiae Scopariae control medicinal material 0.5-1.5g, add water 40-60ml, decocted 0.5-1.5 hour, get supernatant, be concentrated into 10-30ml, with ethyl acetate extraction 1-3 time, 20-40ml, 10-30ml for the second time for the first time, combined ethyl acetate liquid, water bath method, residue add ethyl acetate 0.5-1.5ml makes dissolving, in contrast medical material solution; Draw need testing solution 0.5-1.5 μ l, control medicinal material solution 4-6 μ l, putting respectively on same silica gel g thin-layer plate, is developing solvent with 60-90 ℃ of petroleum ether-ethyl acetate of 0.5-2:0.5-2 ratio, launches, take out, dry, put under the 365nm ultra-violet lamp and observe, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;
B, get this drug combination preparation 4/1000-8/1000 day and use the dosage porphyrize, add 40-60% ethanol 5-25ml, supersound process 10-30 minute, filter, filtrate is as need testing solution; Other gets the peoniflorin reference substance, adds ethanol and makes the solution that every 1ml contains 0.5-1.5mg, in contrast product solution; Test according to thin layer chromatography, drawing each 5-15 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, is developing solvent with the chloroform-ethyl acetate-methanol-formic acid of 30-50:1-10:5-15:0.1-0.3 ratio, launch, take out, dry, spray is with 1-10% vanillin sulfuric acid solution, 100-110 ℃ to be heated to speckle colour developing clear, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
C, get this drug combination preparation 1/100-5/100 day and use dosage, porphyrize, the 20-40ml that adds diethyl ether, reflux, extract, 20-40 minute, filter, filtrate volatilizes, and residue adds ethyl acetate 0.4-0.6ml makes dissolving, as need testing solution; Other gets Radix Angelicae Sinensis control medicinal material 1g, the 5-15ml that adds diethyl ether, and supersound process 5-15 minute, filter, filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, in contrast medical material solution; Test according to thin layer chromatography, draw each 4-6 μ l of above-mentioned two kinds of solution, putting respectively on same silica gel g thin-layer plate, is developing solvent with 60-90 ℃ of petroleum ether-ethyl acetate of 5-15:0.1-1.0 ratio, launches, take out, dry, put under the 365nm ultra-violet lamp and inspect, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;
D, get the tanshinone reference substance, add ethyl acetate and make the solution that every 1ml contains 1-3mg, in contrast product solution; Get this drug combination preparation 1/100-5/100 day and use dosage, porphyrize, 20-40ml adds diethyl ether, reflux, extract, 20-40 minute, filter, filtrate volatilizes, residue adds ethyl acetate 0.4-0.6ml makes dissolving, as need testing solution, draws need testing solution 5-15 μ l, reference substance solution 4-6 μ l, putting respectively on same silica gel g thin-layer plate, is developing solvent with the thiacyclohexane-ethyl acetate of 4-8:1 ratio, launches, take out, dry; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical kermesinus speckle;
E, get this drug combination preparation 1/100-3/100 day and use dosage, porphyrize adds methanol 10-30ml, supersound process 10-30 minute, filter the filtrate evaporate to dryness, residue adds 1.5-3.5mol/L sulfuric acid solution 5-15ml makes dissolving, puts in the water-bath and heats 20-40 minute, immediately cooling, extract twice with the chloroform jolting, each 5-15ml merges chloroform liquid, evaporate to dryness, residue adds methanol 0.5-1.5ml makes dissolving, as need testing solution; Other gets the emodin reference substance, adds methanol and makes the solution that every 1ml contains 0.5-1.5mg, in contrast product solution; Test according to thin layer chromatography, draw each 4-8 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, upper solution with 30~60 ℃ of petroleum ether-Ethyl formate-formic acid of 5-25:4-6:0.5-1.5 ratio is developing solvent, launch, take out, dry, put in the ammonia smoked after, inspect under the daylight; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
Assay: shine high effective liquid chromatography for measuring: chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; The acetonitrile-water of 5-25:70-95 ratio is a mobile phase, and the detection wavelength is 230nm, and number of theoretical plate calculates by the peoniflorin peak should be not less than 2600;
The preparation of reference substance solution: precision takes by weighing peoniflorin reference substance 4-6mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, and promptly gets the reference substance solution that contains peoniflorin 40-60 μ g among every 1ml;
The need testing solution preparation: get this drug combination preparation under the content uniformity item, porphyrize is got 6/10000-1/1000 day and is used dosage, the accurate title, decide, and puts in the tool plug conical flask, and precision adds 50-70% methanol 15-35ml, close plug claims to decide weight, power 250W, frequency 40KHZ supersound process 20-40 minute is taken out, and puts cold, claim again to decide weight, supply minimizing weight, shake up with 50-70% methanol, get supernatant, filter, promptly;
Algoscopy: accurate respectively reference substance solution and each 5-15 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, promptly;
This drug combination preparation contains the Radix Paeoniae Alba with peoniflorin C with dosage every day 23H 28O 11Meter should be less than 50-70mg.
The pass of weight portion of the present invention and parts by volume is a grams per milliliter.
The daily dosage of the different preparations of pharmaceutical composition of the present invention (every day taking dose or every day using dosage) is different because of preparation, but it is identical to contain suitable crude drug amount in the daily dosage of different preparations.Quality determining method of the present invention is a measurement unit with daily dosage.Convert according to the amount of crude drug, adult every day, the amount with the suitable crude drug of dosage was: 280-360g.
Pharmaceutical composition of the present invention confirms through experimentation: has the remarkable effect that recovers ALT, AST, liver function leading indicators such as GGT, BiL to possess instant effect, has no side effect, and safe in utilization, obtain advantages such as imitating the difficult recurrence in back.
The present composition is compared existing preparation and is possessed good drug effect, and the adjuvant technology of pharmaceutical composition of the present invention is found volatile oil and β-cyclodextrin enclose under certain condition and proportioning through screening, can reach curative effect preferably; The method of quality control of Chinese medicine composition provided by the present invention, be by obtaining behind the creative experiment sieving of big measuring, pass through screening in the discrimination method to sample treatment, the selection of developing solvent, make and differentiate that specificity is fine, and method is economic and practical, the result is quick, and can both use different lamellaes.Pass through screening in the content assaying method to sample, test sample processing method, the selection of developing solvent, make content assaying method effectivelyly to carry out quality control, and compare more stable that product that additive method measures shows on drug effect with the product that this method is measured to product.
Description of drawings
Figure of description is volatile oil beta-cyclodextrin inclusion experiment flow figure.
Following experimental example and embodiment are used for further specifying but are not limited to the present invention.
Experimental example 1: the medicine group to protecting liver, lowering enzymes, cholagogic, removing jaundice, engulf the pharmacodynamics test of the ability of cleaning up
Medicine group I: the pharmaceutical composition mixture of getting the embodiment of the invention 2 preparations
Medicine group II: the pharmaceutical composition mixture of getting the embodiment of the invention 13 preparations
Control group: the soothing the liver mixture of commercially available heat-clearing.
One. function for protecting liver and reducing enzyme activity
1. to the protective effect of acute liver damage
Get 84 of kunming mices, body weight 18-20g, male and female half and half are divided into 7 groups at random. First group: Normal group gavages the equivalent drinking water every day; Second group: model group gavages the equivalent drinking water every day; The 3rd group: medicine group I gavages medicine group I soup 30ml (being equivalent to crude drug 9.32g)/kg body weight day; The 4th group: medicine group II gavages medicine group II soup 30ml (being equivalent to crude drug 9.32g)/kg body weight day; The 5th group: control group gavages the soothing the liver mixture 0.3ml/10g of 0.4g/ml heat-clearing (being equivalent to contain crude drug 134g/kg) body weight day. The second~five group, after 14 days, carry out modeling with the injection of D-galactosamine 0.8g/kg body weight mouse peritoneal at successive administration. After modeling last administration in 24 hours half an hour, get blood from mouse orbit, survey SGPT, SGOT content, the results are shown in Table 1.
Table 1 medicine group of the present invention is to the protective effect of D-galactosamine induced mice acute liver damage (X ± SD)
Figure 344576DEST_PATH_S071B9920520071226D000011
Figure 215580DEST_PATH_RE-S071B9920520071022D000061
*Compare with model group:*P<0.05; **P<0.01; 
Experimental result shows, with Normal group relatively, SGPT, SGOT content obviously raise (P<0.01) in the serum of model group; Compare with model group, SGPT, the SGOT content of medicine group I of the present invention, II and control group obviously reduce (P<0.01); And medicine group of the present invention and control group and no significant difference.
2. to the protective effect of alcoholic liver injury
Animal grouping and all the same tests of administration, in administration, the 2nd~6 group gavages 50% liquor (strong, colourless liquor distilled from sorghum, 56 °) 0.5ml/20g modeling. Continuously the modeling administration is 30 days, gets blood after last administration half an hour, surveys serum SGPT, SGOT content, the results are shown in Table 2.
Table 2 medicine group of the present invention is to the protective effect of alcoholic liver injury mouse (X ± SD)
Figure 884459DEST_PATH_RE-S071B9920520071022D000062
*Compare with model group:*P<0.05; **P<0.01; 
Experimental result shows, with normal group relatively, SGPT, SGOT content obviously raise (P<0.01) in the serum of model group. Compare with model group, medicine group of the present invention and control group all can reduce SGPT in the serum, SGOT content (P<0.01); And medicine group of the present invention and control group and no significant difference.
3. to the protective effect of chronic liver injury
Get 72 of Wistar rats, body weight 140~150g, male and female half and half are divided into 6 groups at random. First group: Normal group gavages the equivalent drinking water every day; Second group: model group gavages the equivalent drinking water every day; The 3rd group: medicine group I gavages medicine group I soup 30ml (being equivalent to crude drug 9.32g)/kg body weight day; The 4th group: medicine group II gavages medicine group II soup 30ml (being equivalent to crude drug 9.32g)/kg body weight day; The 5th group: control group gavages the soothing the liver mixture 0.3ml/10g of 0.4g/ml heat-clearing (being equivalent to contain crude drug 134g/kg) body weight day. The second~five group, in administration, use 30%CC14Modeling is carried out in oil solution 0.3ml/100 hypodermic injection, twice weekly. The modeling administration was got blood and is surveyed serum SGOT, SGOT, hydroxyproline, total protein, albumin content, and calculate the A/G value after 3 months continuously, the results are shown in Table 3.
Table 3 medicine group of the present invention is to the protective effect of chronic liver injury rat (X ± SD)
Figure 143402DEST_PATH_RE-S071B9920520071022D000071
*Compare with model group; ,*P<0.05; **P<0.01; 
Experimental result shows, compares with normal group, and SGPT, SGOT content obviously raise (P<0.01) in the serum of model group, and the A/G value obviously reduces, and hydroxyproline content obviously raises; Compare with model group, SGPT, the SGOT content of medicine group of the present invention and control group obviously reduce (P<0.01); Hydroxyproline content obviously reduces (P<0.01) in the obvious rising of the A/G value of medicine group of the present invention (P<0.01) and the serum, and the A/G value notable difference (P<0.05) of control group; And medicine group of the present invention and control group and no significant difference.
Two. to the impact of engulfing clean up ability of mouse reticuloendothelial system to inertia carbon granules in the blood flow
Animal, grouping and administration are tested with acute liver damage, more than respectively organized successive administration 20 days, after administration the 7th, 10 day, the 2nd~5 group of mouse peritoneal injection endoxan 100mg/Kg causes immune function of mice low. After 1 hour, mouse tail vein injects india ink 0.1ml/20g in the last administration, in rear 1,5 minute of injection, gets blood 20 μ l from the vena ophthalmica clump, is dissolved in 2.5ml, in the 0.1%Na2CO3 solution, shakes up, and in 680nm wavelength place colorimetric, measures the OD value. Index K value is cleaned up in calculating. The results are shown in Table 6.
Table 6 medicine group of the present invention is to the impact of macrophage phagocytic function (X ± SD)
Figure 632152DEST_PATH_RE-S071B9920520071022D000072
Figure 634743DEST_PATH_RE-S071B9920520071022D000081
*Compare with model group;**P<0.01 
Experimental result shows, compares with normal group, and the K value of model group obviously reduces (P<0.01). Compare with model group, medicine group of the present invention and control group K value obviously increase (P<0.01).
Experimental example 2 adjuvant screening experiment
Volatile oil beta-cyclodextrin inclusion process conditions preferred
Because volatile oil is easy to scatter and disappear, if therefore volatile oil is directly added, to place and with the passing of time or slightly be heated, volatile oil will lose, thereby has reduced content, influences the curative effect of medicine.For addressing this problem, adopted the method for β-cyclic dextrin clathrate, and adopted orthogonal experiment that the condition of inclusion has been carried out preferably.
Experiment flow is seen Figure of description.
Adopt the saturated water solution method inclusion: take by weighing a certain amount of β-cyclodextrin, add an amount of distilled water, β-cyclodextrin aqueous solution of 5% is made in heating in 70 ℃ of water-baths, under the different temperatures (20 ℃, 40 ℃, 60 ℃) stir, rotating speed is 2500 rev/mins, add quantitative volatile oil, fully stir certain hour, get inclusion complex, stop to stir, with the inclusion complex on a small amount of distilled water flushing agitator, airtight, to put in the refrigerator 12 hours, sucking filtration gets the wet product of β-cyclodextrin, through 40 ℃ of dryings of low temperature, get dry product and weigh, use micro-volatile oil extractor, measure by 2005 editions pharmacopeia (appendix XD) first method, record data calculate.
According to Preliminary experiment results, the factor of analyzing influence β-cyclic dextrin clathrate is set as follows test, the results are shown in Table 8-10:
Table 8 factor level table
Figure 95812DEST_PATH_RE-S071B9920520071022D000082
Table 9 result of the test
Figure 260077DEST_PATH_RE-S071B9920520071022D000083
Table 10 analysis of variance table
F0.1(2,2)=9,F0.05(2,2)=19
Result of the test: intuitive analysis is the result know, factor A〉C〉B, optimum condition is A1B2C2; The results of analysis of variance knows, factor A influence is more remarkable, and B, C factor affecting are not remarkable.Should select A1B1C1, but from table 4 result of the test, the inclusion rate of A1B2C2 is greater than A1B1C1, so be asserted A1B2C2, i.e. volatile oil: β-cyclodextrin is 1:4, and mixing time 30 minutes, inclusion temperature are 40 ℃.
The discrimination test of experimental example 3 Herba Artemisiae Scopariaes
The preparation of blank sample is by medicine group flavour of a drug of the present invention and usage ratio, and autogamy does not contain group's medicine of Herba Artemisiae Scopariae, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati respectively, makes blank preparation by preparation technology.
The preparation of blank solution is got the blank sample of this drug combination preparation Herba Artemisiae Scopariae and was used dosage on 14/1000th, adds water 20ml and makes dissolving, uses ethyl acetate extraction 2 times, 30ml for the first time, 20ml for the second time, combined ethyl acetate liquid, water bath method, residue add ethyl acetate 1ml makes dissolving, as blank solution.
This medicine group and the matter sample of same amount got in the preparation of sample solution, gets sample solution according to the system each side legal system of blank solution.
Herba Artemisiae Scopariae control medicinal material 1g is got in the preparation of control medicinal material solution, add water 50ml, decocted 1 hour, get supernatant, be concentrated into 20ml, with ethyl acetate extraction 2 times, 30ml, 20ml for the second time for the first time, combined ethyl acetate liquid, water bath method, residue add ethyl acetate 1ml makes dissolving, in contrast medical material solution.
Following developing solvent is prepared in the selection of developing solvent respectively, 60-90 ℃ of petroleum ether-ethyl acetate 1:4,60-90 ℃ of petroleum ether-ethyl acetate 1:1,60-90 ℃ of petroleum ether-ethyl acetate 4:1
Above three kinds of solution are put respectively on same silica gel g thin-layer plate, respectively with 1:4,1:1, the 60-90 of 4:1 ratio ℃ petroleum ether-ethyl acetate is developing solvent, launch, take out, dry, put under the 365nm ultra-violet lamp and observe, when 60-90 ℃ of petroleum ether-ethyl acetate with the 1:1 ratio is developing solvent in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, the fluorescence speckle of tangible same color is arranged, and blank solution no fluorescence speckle demonstration on corresponding position.
The discrimination test of experimental example 4 Radix Paeoniae Albas
The preparation of blank solution is got this pharmaceutical composition blank and preparation 4/1000-8/1000 day is used the dosage porphyrize, adds 40-60% ethanol 5-25ml, and supersound process 10-30 minute, filter, filtrate is as blank solution.
This medicine group and the matter sample of same amount got in the preparation of sample solution, makes sample solution according to the preparation method of blank solution.
The peoniflorin reference substance is got in the preparation of control medicinal material solution in addition, adds ethanol and makes the solution that every 1ml contains 1mg, in contrast product solution.
The selection preparation 30:10:5:0.3 ratio of developing solvent, the 40:5:10:0.2 ratio, the chloroform-ethyl acetate of 50:1:15:0.1 ratio-methanol-formic acid is developing solvent
Test according to thin layer chromatography, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, in above-mentioned developing solvent, launch respectively, take out, dry, spray is with 5% vanillin sulfuric acid solution, and 105 ℃ of heating are in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color; Wherein, the most obvious in the chloroform-ethyl acetate-methanol-formic acid developing solvent of 40:5:10:0.2 ratio.
Experimental example 5 Radix Angelicae Sinensis are differentiated
The preparation of blank solution is got the blank preparation of this pharmaceutical composition and was used the dosage porphyrize on 3/100th, the 30ml that adds diethyl ether, and reflux, extract, 30 minutes filters, and filtrate volatilizes, and residue adds ethyl acetate 0.5ml makes dissolving, as blank solution.
This medicine group and the matter sample of same amount got in the preparation of sample solution, makes sample solution according to the preparation method of blank solution.
Radix Angelicae Sinensis control medicinal material 1g is got in the preparation of control medicinal material solution, the 10ml that adds diethyl ether, and supersound process 10 minutes filters, and filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, in contrast medical material solution.
The 5:1 ratio is prepared in the selection of developing solvent respectively, the 19:1 ratio, the 60-90 of 150:1 ratio ℃ petroleum ether-ethyl acetate is developing solvent.
Test according to thin layer chromatography, draw each 5 μ l of above-mentioned three kinds of solution, put respectively on same silica gel g thin-layer plate, under above-mentioned developing solvent condition, launch respectively, take out, dry, put under the 365nm ultra-violet lamp and inspect, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color; Wherein, speckle is the most obvious when 60-90 ℃ of petroleum ether-ethyl acetate of 19:1 ratio is developing solvent.
The discrimination test of experimental example 6 Radix Salviae Miltiorrhizaes
The preparation of blank solution is got the blank preparation of this pharmaceutical composition and was used the dosage porphyrize on 3/100th, the 30ml that adds diethyl ether, and reflux, extract, 30 minutes filters, and filtrate volatilizes, and residue adds ethyl acetate 0.5ml makes dissolving, as blank solution.
This medicine group and the matter sample of same amount got in the preparation of sample solution, makes sample solution according to the preparation method of blank solution.
The tanshinone reference substance is got in the preparation of control medicinal material solution, adds ethyl acetate and makes the solution that every 1ml contains 2mg, in contrast product solution.
The 4:1 ratio is prepared in the selection of developing solvent respectively, the 6:1 ratio, the thiacyclohexane-ethyl acetate of 8:1 ratio is developing solvent.
According to the thin layer chromatography test, draw each 10 μ l of blank solution and sample solution, reference substance solution 5 μ l put respectively on same silica gel g thin-layer plate, launch under above-mentioned developing solvent condition respectively, take out, and dry; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical kermesinus speckle.Wherein, speckle is the most obvious when the thiacyclohexane-ethyl acetate of 6:1 ratio is developing solvent.
Experimental example 7 Rhizoma Polygoni Cuspidati are differentiated
The Rhizoma Polygoni Cuspidati main component is an anthracene derivant, and the emodin of this experiment after with hydrolysis in the Rhizoma Polygoni Cuspidati serves as that index is known in inspection, has set up the TLC inspection knowledge method of Rhizoma Polygoni Cuspidati in the preparation.
The preparation of blank solution is got the blank preparation of this pharmaceutical composition and was used the dosage porphyrize on the 14/1000th, and porphyrize adds methanol 20ml, supersound process 20 minutes filters the filtrate evaporate to dryness, residue adds 2.5mol/L sulfuric acid solution 10ml makes dissolving, puts in the water-bath and heats 30 minutes, immediately cooling, extract twice with the chloroform jolting, each 10ml merges chloroform liquid, evaporate to dryness, residue adds methanol 1ml makes dissolving, as blank solution.
This medicine group and the matter sample of same amount got in the preparation of sample solution, makes sample solution according to the preparation method of blank solution.
The emodin reference substance is got in the preparation of control medicinal material solution, adds methanol and makes the solution that every 1ml contains 1mg, in contrast product solution.
The 5:6:0.5 ratio is prepared in the selection of developing solvent respectively, the 15:5:1 ratio, the upper solution of 30~60 ℃ of petroleum ether-Ethyl formate-formic acid of 25:4:1.5 ratio.
According to the thin layer chromatography test, draw blank solution and sample solution, each 6 μ l of reference substance solution, put respectively on same silica gel g thin-layer plate, under above-mentioned developing solvent condition, launch respectively, take out, dry; Put in the ammonia smoked after, inspect under the daylight; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color; Wherein, with the upper solution of 30~60 ℃ of petroleum ether-Ethyl formate-formic acid of 15:5:1 ratio be developing solvent when launching speckle the most obvious.
Experimental example 8 assays
1. instrument and medicine
The HP1050 of U.S. Hewlett-Packard type high performance liquid chromatograph, quaternary pump, DAD detector, chem workstation; H66025 type ultrasonic cleaner (Ultrasound Electronic Equipment Factory, Wuxi City); Acetonitrile is a chromatographically pure, and mobile phase institute water is a distilled water.
2. the optimization of chromatographic condition
Chromatographic column is YWGC18,10 μ m, and 4.6 * 250mm, the Dalian Chemistry and Physics Institute, post is imitated and is not less than 2600 in its theoretical cam curve of paeoniflorin; Mobile phase is acetonitrile-water (15:85); Flow velocity is 1ml/min; The detection wavelength is 230nm, and column temperature is a room temperature, and the ratio of acetonitrile in the mobile phase and water is studied, and has optimized chromatographic condition.
Prepare the mobile phase of following ratio respectively: acetonitrile-water (15:75), acetonitrile-water (15:80), acetonitrile-water (15:85), acetonitrile-water (15:90), acetonitrile-water (15:95)
By above chromatographic condition sample introduction reference substance, sample, the results are shown in following table 11 respectively:
The optimization of table 11 chromatographic condition
The result as can be known, other chromatograph when mobile phase is acetonitrile-water (15:75), acetonitrile-water (15:80) in the sample can not be separated fully with the peoniflorin chromatographic peak, and with acetonitrile-water (15:90), when acetonitrile-water (15:95) is mobile phase, holder tail phenomenon appears in the peoniflorin chromatographic peak.Preferred flow is acetonitrile-water (15:85) mutually
3. sample extraction solvent and optimization for extracting condition
The extraction solvent commonly used of paeoniflorin is water, methanol, ethanol and rare alcohol, and this experiment is adopted methanol aqueous solution can avoid water for the sample extraction solvent and caused the too much phenomenon generation of impurity as extracting solvent.To methanol aqueous solution concentration, solubilizer multiple and ultrasonic treatment time have been done comparative study, have optimized the extraction conditions of sample.
Optimization for extracting condition sample thief powder (lot number 060529), porphyrize (crossing 50 mesh sieves), precision takes by weighing five parts of 0.25g, the accurate 60% methanol 25ml that adds of No.1~No.5 weighs close plug, according to the form below is supersound process (power 250W, frequency 40KHZ) respectively, and extraction finishes, take out, weigh, supply the quantity of solvent that loses, get supernatant with 0.45 μ m filtering with microporous membrane, filtrate is as need testing solution, by above-mentioned chromatographic condition, sample introduction 20 μ l measure, and measurement result is added up, and the results are shown in Table 12.
Table 12 extraction time investigation (content of paeoniflorin mg/g)
Figure 858286DEST_PATH_S071B9920520071022D000132
The result is as can be known: no significant difference between each group.But the content with ultrasonic 10 minutes and 20 minutes is lower slightly.30 minutes, 40 minutes content basically identicals.
According to above method, be under the condition of 30min in extraction time, investigate the concentration of extracting solution, the results are shown in following table 13
Table 13 extract concentration is investigated (content of paeoniflorin mg/g)
Figure 202680DEST_PATH_S071B9920520071022D000141
The result is as can be known: no significant difference between each group, to extract with 60% methanol solution, and the paeoniflorin yield is higher.
According to above method, be 30min in extraction time, extracting solution is under the condition of 60% methanol, investigates the solubilizer multiple, the results are shown in Table 14.
The investigation of table 14 solubilizer multiple (content of paeoniflorin mg/g)
Figure 700657DEST_PATH_S071B9920520071022D000142
The result is as can be known: no significant difference between each group, it is higher to add under 100 times of amount solvent conditions the paeoniflorin yield.
Conclusion: determine that extraction conditions is 60% methanol, 25ml, ultrasonic 30 minutes.
4. stability test
Get need testing solution (060529), respectively at preparation back 0,2,4,6,10,16,24 hour, measure in accordance with the law, the result shows, and is basicly stable in 24 hours, the results are shown in Table 15.
Table 15 stability test
5. precision test
Accurate paeoniflorin reference substance solution (C=0.204mg/ml) the 10 μ l that draw repeat sample introduction 5 times by aforementioned chromatographic condition, record peak area, and trying to achieve RSD is 1.13%, the results are shown in Table 16.
Table 16 Precision test result
Figure 422943DEST_PATH_S071B9920520071022D000151
6. linear relationship is investigated
Accurate draw the paeoniflorin reference substance solution (2.5,5,7.5,10,12.5,15, the 20 μ l of 2.10mg → 10ml) measure by above-mentioned chromatographic condition sample introduction, measure peak area, the results are shown in Table 9.With peak area the amount of reference substance is carried out linear regression (comprising initial point), trying to achieve regression equation is Y=-39.6975+1574.5933X, and r=0.9999 shows that paeoniflorin is linear in 0.525~4.200 μ g scope, and testing result sees Table 17.
Table 17 paeoniflorin standard curve determination result
Figure 243131DEST_PATH_S071B9920520071022D000152
7. repeatability test
Get same batch sample (lot number 060529) porphyrize, precision takes by weighing 0.25g, and totally five parts, measure by the text method, try to achieve relative standard deviation.The results are shown in Table 18.
Table 18 reproducible test results
Figure 595615DEST_PATH_S071B9920520071022D000153
Figure 272584DEST_PATH_S071B9920520071022D000161
8. blank assay
Do not contain group's medicine of the Radix Paeoniae Alba in the autogamy of prescription taste of Chinese medicine ratio, make blank solution by the text method.Blank solution does not show obvious chromatographic peak at the place of identical retention time with paeoniflorin as a result, thinks noiseless.
9. recovery test
Adopt the application of sample absorption method, precision takes by weighing totally five parts of same lot number sample (lot number 060529) (content the is 6.9mg/g) 0.15g of known content, according to the form below adds paeoniflorin reference substance solution (concentration 0.234mg/ml) 5ml respectively, the accurate again 20ml60% methanol that adds, close plug, extract and measure by sample extraction and condition determination,, the results are shown in Table 19 with the following formula calculate recovery rate.
Figure 710519DEST_PATH_S071B9920520071022D000162
Table 19 recovery test result
Figure 396715DEST_PATH_S071B9920520071022D000163
10. sample determination result
Record method by text ten batch samples are measured, the results are shown in Table 20.
Table 20 sample determination result
Figure 603705DEST_PATH_S071B9920520071022D000164
Figure 654838DEST_PATH_S071B9920520071022D000171
According to above data, it is that the every gram of this product contains the Radix Paeoniae Alba by paeoniflorin (C that content limit is fixed tentatively 23H 28O 11) meter, should be no less than 5.0mg.
Experimental example 9. content assaying methods of the present invention are the employment and suitability test (E ﹠ ST) in the content of paeoniflorin mensuration in qizhi weitong granules
Qizhi weitong granules mainly is made up of Radix Bupleuri, Rhizoma Corydalis, Fructus Aurantii, Rhizoma Cyperi, the Radix Paeoniae Alba, Radix Glycyrrhizae Preparata Six-element Chinese medicine.Peoniflorin is the index components of control this product quality, and pilot production is measured content of paeoniflorin in the qizhi weitong granules with this method.
(1) repeatability test
Get same batch sample (lot number 060312) porphyrize, precision takes by weighing 0.25g, and totally five parts, measure by the text method, try to achieve relative standard deviation.The results are shown in Table 21.
Table 21 reproducible test results
Figure 580069DEST_PATH_S071B9920520071022D000172
(2) recovery test
Adopt the application of sample absorption method, precision takes by weighing totally five parts of same lot number sample (lot number 060312) (content the is 1.5mg/g) 0.85g of known content, according to the form below adds paeoniflorin reference substance solution (concentration 0.234mg/ml) 5ml respectively, the accurate again 20ml60% methanol that adds, close plug, extract and measure by sample extraction and condition determination,, the results are shown in Table 22 with the following formula calculate recovery rate.
Figure 804377DEST_PATH_S071B9920520071022D000181
Table 22 recovery test result
Figure 131453DEST_PATH_S071B9920520071022D000182
According to above presentation of results, this content assaying method is used for measuring qizhi weitong granules content of paeoniflorin poor reproducibility, the response rate is low.Though illustrate in the multiple Chinese patent medicine and contain peoniflorin, its assay method is often different.
Following embodiment all can realize the described effect of above-mentioned experimental example
Embodiment 1
Poria 960g, Herba Artemisiae Scopariae 960g, Rhizoma Atractylodis Macrocephalae 960g, Radix Curcumae 320g, Radix Angelicae Sinensis 480g, succinum 50-150g, the Radix Paeoniae Alba (stir-fry) 960g, Herba Scutellariae Barbatae 960g, Fructus Amomi 192g, Rhizoma Polygoni Cuspidati 480g, Radix Salviae Miltiorrhizae 960g, Herba Lycopi 480g, Radix Bupleuri 320g, Herba Pogostemonis 320g, Herba Eupatorii 480g, Flos Carthami 320g
This pharmaceutical composition adds conventional adjuvant, makes capsule by common process.
Embodiment 2
Poria 520g, Herba Artemisiae Scopariae 1480g, Rhizoma Atractylodis Macrocephalae 520g, Radix Curcumae 430g, Radix Angelicae Sinensis 270g, succinum 130g, the Radix Paeoniae Alba (stir-fry) 520g, Herba Scutellariae Barbatae 1480g, Fructus Amomi 120g, Rhizoma Polygoni Cuspidati 730g, Radix Salviae Miltiorrhizae 520g, Herba Lycopi 730g, Radix Bupleuri 170g, Herba Pogostemonis 430g, Herba Eupatorii 270g, Flos Carthami 430g
Radix Angelicae Sinensis, Radix Curcumae, Herba Pogostemonis, Herba Eupatorii, Fructus Amomi, Herba Lycopi extracted volatile oil 8 hours, and the aqueous solution after distillation device is in addition collected; Volatile oil is with 40 ℃ of inclusions of beta-schardinger dextrin-saturated water solution method of 4 times of weight portions, 40 ℃ of dryings, the volatile oil beta-cyclodextrin inclusion complex, standby; Radix Salviae Miltiorrhizae is with 85% alcohol reflux of 6 times of weight portions 2 times, and each 1 hour, merge extractive liquid, filtered, and filtrate recycling ethanol is not to there being the alcohol flavor, Radix Salviae Miltiorrhizae extract, standby; Medicinal residues and all the other flavour of a drug decoct with water 2 times, add 8 times of water gagings at every turn and decoct 1.5 hours, and collecting decoction filters; Aqueous solution after filtrate and the above-mentioned distillation merges, be concentrated into 60~65 ℃ of relative densities and be 1.02~1.04 thick paste I, add ethanol and make and contain alcohol amount and reach 70%, left standstill 24 hours, filter, filtrate recycling ethanol is to an amount of, merge with above-mentioned Radix Salviae Miltiorrhizae extract, and the thick paste II that to be concentrated into 60~65 ℃ of relative densities be 1.10-1.15, add 80% simple syrup 960 parts by volume, the volatile oil beta-cyclodextrin inclusion complex is ground into fine powder, adds in the extractum; Add sodium benzoate 9.6g again, stir evenly, add water to 3000 parts by volume, filter, fill, sterilization promptly gets mixture and used dosage on the 30th.
Embodiment 3
Poria 1480g, Herba Artemisiae Scopariae 520g, Rhizoma Atractylodis Macrocephalae 1480g, Radix Curcumae 170g, Radix Angelicae Sinensis 730g, succinum 70g, the Radix Paeoniae Alba (stir-fry) 1480g, Herba Scutellariae Barbatae 520g, Fructus Amomi 280g, Rhizoma Polygoni Cuspidati 270g, Radix Salviae Miltiorrhizae 1480g, Herba Lycopi 270g, Radix Bupleuri 430g, Herba Pogostemonis 170g, Herba Eupatorii 730g, Flos Carthami 170g
Radix Angelicae Sinensis, Radix Curcumae, Herba Pogostemonis, Herba Eupatorii, Fructus Amomi, Herba Lycopi extracted volatile oil 8 hours, and the aqueous solution after distillation device is in addition collected; Volatile oil is with 40 ℃ of inclusions of beta-schardinger dextrin-saturated water solution method of 4 times of weight portions, 40 ℃ of dryings, the volatile oil beta-cyclodextrin inclusion complex, standby; Radix Salviae Miltiorrhizae is with 85% alcohol reflux of 6 times of weight portions 2 times, and each 1 hour, merge extractive liquid, filtered, and filtrate recycling ethanol is not to there being the alcohol flavor, Radix Salviae Miltiorrhizae extract, standby; Medicinal residues and all the other flavour of a drug decoct with water 2 times, add 8 times of water gagings at every turn and decoct 1.5 hours, and collecting decoction filters; Aqueous solution after filtrate and the above-mentioned distillation merges, and is concentrated into 60~65 ℃ of relative densities and is 1.02~1.04 thick paste I, adds ethanol and makes and contain the alcohol amount and reach 70%, left standstill 24 hours, and filtered, filtrate recycling ethanol is to an amount of, merge with above-mentioned Radix Salviae Miltiorrhizae extract, and be concentrated into 60~65 ℃ of relative densities and be
1.25-1.30 thick paste II, drying under reduced pressure under 0.08Mpa, the 65 ℃ of conditions adds the volatile oil beta-cyclodextrin inclusion complex, is ground into fine powder; 70% ethanol system soft material, extrusion granulator promptly gets and used dosage on the 32nd.
Embodiment 4
Poria 960g, Herba Artemisiae Scopariae 960g, Radix Curcumae 320g, Radix Angelicae Sinensis 480g, succinum 96g, the Radix Paeoniae Alba (stir-fry) 960g, Herba Scutellariae Barbatae 960g, Fructus Amomi 192g, Rhizoma Polygoni Cuspidati 480g, Radix Salviae Miltiorrhizae 960g, Herba Lycopi 480g, Radix Bupleuri 320g, Herba Pogostemonis 320g, Herba Eupatorii 480g, Flos Carthami 320g, Radix Isatidis 960g, Rhizoma Dryopteris Crassirhizomatis 480g, Herba Hedyotidis Diffusae 960g, Rhizoma Paridis 480g
This pharmaceutical composition adds conventional adjuvant, makes mixture by common process.
Embodiment 5
Poria 520g, Herba Artemisiae Scopariae 1480g, Radix Curcumae 170g, Radix Angelicae Sinensis 730g, succinum 70g, the Radix Paeoniae Alba (stir-fry) 1480g, Herba Scutellariae Barbatae 520g, Fructus Amomi 280g, Rhizoma Polygoni Cuspidati 270g, Radix Salviae Miltiorrhizae 1480g, Herba Lycopi 270g, Radix Bupleuri 430g, Herba Pogostemonis 170g, Herba Eupatorii 730g, Flos Carthami 170g, Radix Isatidis 1480g, Rhizoma Dryopteris Crassirhizomatis 270g, Herba Hedyotidis Diffusae 1480g, Rhizoma Paridis 270g
This pharmaceutical composition adds conventional adjuvant, makes tablet by common process.
Embodiment 6
Poria 1480g, Herba Artemisiae Scopariae 520g, Radix Curcumae 430g, Radix Angelicae Sinensis 270g, succinum 130g, the Radix Paeoniae Alba (stir-fry) 520g, Herba Scutellariae Barbatae 1480g, Fructus Amomi 120g, Rhizoma Polygoni Cuspidati 730g, Radix Salviae Miltiorrhizae 520g, Herba Lycopi 730g, Radix Bupleuri 170g, Herba Pogostemonis 430g, Herba Eupatorii 270g, Flos Carthami 430g, Radix Isatidis 520g, Rhizoma Dryopteris Crassirhizomatis 730g, Herba Hedyotidis Diffusae 520g, Rhizoma Paridis 730g
Radix Angelicae Sinensis, Radix Curcumae, Herba Pogostemonis, Herba Eupatorii, Fructus Amomi, Herba Lycopi extracted volatile oil 8 hours, and the aqueous solution after distillation device is in addition collected; Volatile oil is with 40 ℃ of inclusions of beta-schardinger dextrin-saturated water solution method of 4 times of weight portions, 40 ℃ of dryings, the volatile oil beta-cyclodextrin inclusion complex, standby; Radix Salviae Miltiorrhizae is with 85% alcohol reflux of 6 times of weight portions 2 times, and each 1 hour, merge extractive liquid, filtered, and filtrate recycling ethanol is not to there being the alcohol flavor, Radix Salviae Miltiorrhizae extract, standby; 12 flavors such as medicinal residues and all the other Herba Artemisiae Scopariaes decoct with water 2 times, add 8 times of water gagings at every turn and decoct 1.5 hours, and collecting decoction filters; Aqueous solution after filtrate and the above-mentioned distillation merges, be concentrated into 60~65 ℃ of relative densities and be 1.02~1.04 thick paste I, add ethanol and make and contain alcohol amount and reach 70%, left standstill 24 hours, filter, filtrate recycling ethanol is to an amount of, merge with above-mentioned Radix Salviae Miltiorrhizae extract, and the thick paste II that to be concentrated into 60~65 ℃ of relative densities be 1.10-1.15, add 80% simple syrup 1000 parts by volume, the volatile oil beta-cyclodextrin inclusion complex is ground into fine powder, adds in the extractum; Add sodium benzoate 9.6g again, stir evenly, add water to 3600 parts by volume, filter, fill, sterilization promptly gets mixture.
The method of quality control of embodiment 7 preparations of the present invention
Differentiate: A, get the content of 0.014 times of daily dosage of this medicament composition granule agent of embodiment 3 preparations, add water 20ml and make dissolving, with ethyl acetate extraction 2 times, 30ml for the first time, 20ml for the second time, combined ethyl acetate liquid, water bath method, residue adds ethyl acetate 1ml makes dissolving, as need testing solution; Other gets Herba Artemisiae Scopariae control medicinal material 1g, adds water 50ml, decocts 1 hour, gets supernatant, be concentrated into 20ml, use ethyl acetate extraction 2 times, for the first time 30ml, 20ml for the second time, combined ethyl acetate liquid, water bath method, residue add ethyl acetate 1ml makes dissolving, in contrast medical material solution; Draw need testing solution 1 μ l, control medicinal material solution 5 μ l, putting respectively on same silica gel g thin-layer plate, is developing solvent with 60-90 ℃ of petroleum ether-ethyl acetate of 1:1 ratio, launches, take out, dry, put under the 365nm ultra-violet lamp and observe, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;
B, get the content of 0.0057 times of daily dosage of this medicament composition granule agent of embodiment 3 preparation, porphyrize adds 50% ethanol 15ml, and supersound process 20 minutes filters, and filtrate is as need testing solution; Other gets the peoniflorin reference substance, adds ethanol and makes the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography, drawing each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, is developing solvent with the chloroform-ethyl acetate-methanol-formic acid of 40:5:10:0.2 ratio, launch, take out, dry, spray is with 5% vanillin sulfuric acid solution, 105 ℃ to be heated to speckle colour developing clear, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
C, get the content of 0.029 times of daily dosage of this medicament composition granule agent of embodiment 3 preparation, porphyrize, the 30ml that adds diethyl ether, reflux, extract, 30 minutes filters, and filtrate volatilizes, and residue adds ethyl acetate 0.5ml makes dissolving, as need testing solution; Other gets Radix Angelicae Sinensis control medicinal material 1g, the 10ml that adds diethyl ether, and supersound process 10 minutes filters, and filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, in contrast medical material solution; Test according to thin layer chromatography, draw each 5 μ l of above-mentioned two kinds of solution, putting respectively on same silica gel g thin-layer plate, is developing solvent with 60-90 ℃ of petroleum ether-ethyl acetate of 9.5:0.5 ratio, launches, take out, dry, put under the 365nm ultra-violet lamp and inspect, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;
D, get the tanshinone reference substance, add ethyl acetate and make the solution that every 1ml contains 2mg, in contrast product solution; According to thin layer chromatography test, draw and differentiate C item need testing solution 10 μ l down, reference substance solution 5 μ l put respectively on same silica gel g thin-layer plate, are developing solvent with the thiacyclohexane-ethyl acetate of 6:1 ratio, launch, and taking-up is dried; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical kermesinus speckle.
The method of quality control of embodiment 8 preparations of the present invention
Assay: shine high effective liquid chromatography for measuring: chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; The acetonitrile-water of 15:85 ratio is a mobile phase, and the detection wavelength is 230nm, and number of theoretical plate calculates by the peoniflorin peak should be not less than 2600;
The preparation of reference substance solution: precision takes by weighing peoniflorin reference substance 5mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, and promptly gets the reference substance solution that contains peoniflorin 50 μ g among every 1ml;
The need testing solution preparation: get the content of 0.00072 times of daily dosage of this pharmaceutical composition mixture of embodiment 2 preparations under the content uniformity item, the accurate title, decide, and puts in the tool plug conical flask, precision adds 60% methanol 25ml, and close plug claims to decide weight, power 250W, frequency 40KHZ supersound process 30 minutes is taken out, put coldly, claim again to decide weight, supply minimizing weight with 60% methanol, shake up, get supernatant, filter, promptly;
Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, promptly;
This pharmaceutical composition mixture contains the Radix Paeoniae Alba with peoniflorin C with dosage every day 23H 28O 11Meter should be less than 60mg.
Embodiment 9
Differentiate: A, get the content of 0.014 times of daily dosage of this pharmaceutical composition mixture of embodiment 2 preparations, add water 20ml and make dissolving, with ethyl acetate extraction 2 times, 30ml for the first time, 20ml for the second time, combined ethyl acetate liquid, water bath method, residue adds ethyl acetate 1ml makes dissolving, as need testing solution; Other gets Herba Artemisiae Scopariae control medicinal material 1g, adds water 50ml, decocts 1 hour, gets supernatant, be concentrated into 20ml, use ethyl acetate extraction 2 times, for the first time 30ml, 20ml for the second time, combined ethyl acetate liquid, water bath method, residue add ethyl acetate 1ml makes dissolving, in contrast medical material solution; Draw need testing solution 1 μ l, control medicinal material solution 5 μ l, putting respectively on same silica gel g thin-layer plate, is developing solvent with 60-90 ℃ of petroleum ether-ethyl acetate of 1:1 ratio, launches, take out, dry, put under the 365nm ultra-violet lamp and observe, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;
B, get the content of 0.0057 times of daily dosage of this pharmaceutical composition mixture of embodiment 2 preparation, porphyrize adds 50% ethanol 15ml, and supersound process 20 minutes filters, and filtrate is as need testing solution; Other gets the peoniflorin reference substance, adds ethanol and makes the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography, drawing each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, is developing solvent with the chloroform-ethyl acetate-methanol-formic acid of 40:5:10:0.2 ratio, launch, take out, dry, spray is with 5% vanillin sulfuric acid solution, 105 ℃ to be heated to speckle colour developing clear, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
C, get the content of 0.029 times of daily dosage of this pharmaceutical composition mixture of embodiment 2 preparation, porphyrize, the 30ml that adds diethyl ether, reflux, extract, 30 minutes filters, and filtrate volatilizes, and residue adds ethyl acetate 0.5ml makes dissolving, as need testing solution; Other gets Radix Angelicae Sinensis control medicinal material 1g, the 10ml that adds diethyl ether, and supersound process 10 minutes filters, and filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, in contrast medical material solution; Test according to thin layer chromatography, draw each 5 μ l of above-mentioned two kinds of solution, putting respectively on same silica gel g thin-layer plate, is developing solvent with 60-90 ℃ of petroleum ether-ethyl acetate of 9.5:0.5 ratio, launches, take out, dry, put under the 365nm ultra-violet lamp and inspect, in the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;
Assay: shine high effective liquid chromatography for measuring: chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; The acetonitrile-water of 15:85 ratio is a mobile phase, and the detection wavelength is 230nm, and number of theoretical plate calculates by the peoniflorin peak should be not less than 2600;
The preparation of reference substance solution: precision takes by weighing peoniflorin reference substance 5mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, and promptly gets the reference substance solution that contains peoniflorin 50 μ g among every 1ml;
The need testing solution preparation: get 0.00072 times of daily dosage content of this pharmaceutical composition mixture of embodiment 12 preparations under the content uniformity item, the accurate title, decide, and puts in the tool plug conical flask, precision adds 60% methanol 25ml, and close plug claims to decide weight, power 250W, frequency 40KHZ supersound process 30 minutes is taken out, put coldly, claim again to decide weight, supply minimizing weight with 60% methanol, shake up, get supernatant, filter, promptly;
Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, promptly;
The agent of this medicament composition capsule contains the Radix Paeoniae Alba with peoniflorin C with dosage every day 23H 28O 11Meter should be less than 60mg.
Embodiment 10
Herba Artemisiae Scopariae 960g, Radix Isatidis 960g, Rhizoma Dryopteris Crassirhizomatis 480g, Poria 960g, Radix Curcumae 320g, Radix Angelicae Sinensis 480g, Flos Carthami 320g, succinum 96g, the Radix Paeoniae Alba (stir-fry) 960g, Herba Hedyotidis Diffusae 960g, Herba Scutellariae Barbatae 960g, Herba Pogostemonis 320g, Herba Eupatorii 480g, Fructus Amomi 192g, Rhizoma Polygoni Cuspidati 480g, Radix Salviae Miltiorrhizae 960g, Herba Lycopi 480g, Radix Bupleuri 320g, Rhizoma Paridis 480g
More than 19 flavors, Radix Angelicae Sinensis, Radix Curcumae, Herba Pogostemonis, Herba Eupatorii, Fructus Amomi, Herba Lycopi extracted volatile oil 8 hours, the aqueous solution after the distillation in addition device is collected; Volatile oil is with 40 ℃ of inclusions of beta-schardinger dextrin-saturated water solution method of 4 times of weight portions, 40 ℃ of dryings, the volatile oil beta-cyclodextrin inclusion complex, standby; Radix Salviae Miltiorrhizae is with 85% alcohol reflux of 6 times of weight portions 2 times, and each 1 hour, merge extractive liquid, filtered, and filtrate recycling ethanol is not to there being the alcohol flavor, Radix Salviae Miltiorrhizae extract, standby; 12 flavors such as medicinal residues and all the other Herba Artemisiae Scopariaes decoct with water 2 times, add 8 times of water gagings at every turn and decoct 1.5 hours, and collecting decoction filters; Aqueous solution after filtrate and the above-mentioned distillation merges, be concentrated into 60~65 ℃ of relative densities and be 1.02~1.04 thick paste I, adding ethanol makes and contains alcohol amount and reach 70%, left standstill 24 hours, and filtered, filtrate recycling ethanol is to an amount of, merge with above-mentioned Radix Salviae Miltiorrhizae extract, and the thick paste II that to be concentrated into 60~65 ℃ of relative densities be 1.10-1.15, adding 80% simple syrup 960 parts by volume, the volatile oil beta-cyclodextrin inclusion complex is ground into fine powder; Add sodium benzoate 9.6g again, add water to 3200 parts by volume, filter, fill, sterilization promptly gets mixture.
The method of quality control of embodiment 11 preparations of the present invention
Assay: shine high effective liquid chromatography for measuring: chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; The acetonitrile-water of 15:85 ratio is a mobile phase, and the detection wavelength is 230nm, and number of theoretical plate calculates by the peoniflorin peak should be not less than 2600;
The preparation of reference substance solution: precision takes by weighing peoniflorin reference substance 5mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, and promptly gets the reference substance solution that contains peoniflorin 50 μ g among every 1ml;
The need testing solution preparation: get this medicament composition capsule agent of embodiment 1 preparation under the content uniformity item, porphyrize is got 0.00072 times daily dosage, the accurate title, decide, and puts in the tool plug conical flask, and precision adds 60% methanol 25ml, close plug claims to decide weight, power 250W, frequency 40KHZ supersound process 30 minutes is taken out, and puts cold, claim again to decide weight, supply minimizing weight, shake up with 60% methanol, get supernatant, filter, promptly;
Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, promptly;
The agent of this medicament composition capsule contains the Radix Paeoniae Alba with peoniflorin C with dosage every day 23H 28O 11Meter should be less than 60mg.
The method of quality control of embodiment 12 preparations of the present invention
Differentiate:
A, get the daily dosage content porphyrize of 0.0057 times in this pharmaceutical composition mixture of embodiment 6 preparation, add 50% ethanol 15ml, supersound process 20 minutes filters, and filtrate is as need testing solution; Other gets the peoniflorin reference substance, adds ethanol and makes the solution that every 1ml contains 1mg, in contrast product solution; Test according to thin layer chromatography, drawing each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, is developing solvent with the chloroform-ethyl acetate-methanol-formic acid of 40:5:10:0.2 ratio, launch, take out, dry, spray is with 5% vanillin sulfuric acid solution, 105 ℃ to be heated to speckle colour developing clear, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
B, get the tanshinone reference substance, add ethyl acetate and make the solution that every 1ml contains 2mg, in contrast product solution; According to thin layer chromatography test, get the daily dosage content of 0.029 times in this pharmaceutical composition mixture of embodiment 6 preparations, porphyrize, the 30ml that adds diethyl ether, reflux, extract, 30 minutes filters, filtrate volatilizes, and residue adds ethyl acetate 0.5ml makes dissolving, as need testing solution, draw need testing solution 10 μ l, reference substance solution 5 μ l put respectively on same silica gel g thin-layer plate, thiacyclohexane-ethyl acetate with the 6:1 ratio is developing solvent, launch, take out, dry; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical kermesinus speckle;
C, get the daily dosage content of 0.014 times in this pharmaceutical composition mixture of embodiment 6 preparation, porphyrize adds methanol 20ml, supersound process 20 minutes filters the filtrate evaporate to dryness, residue adds 2.5mol/L sulfuric acid solution 10ml makes dissolving, puts in the water-bath and heats 30 minutes, immediately cooling, extract twice with the chloroform jolting, each 10ml merges chloroform liquid, evaporate to dryness, residue adds methanol 1ml makes dissolving, as need testing solution; Other gets the emodin reference substance, adds methanol and makes the solution that every 1ml contains 1mg, in contrast product solution; According to the thin layer chromatography test, draw each 6 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, upper solution with 30~60 ℃ of petroleum ether-Ethyl formate-formic acid of 15:5:1 ratio is developing solvent, launches, and takes out, dry, put in the ammonia smoked after, inspect under the daylight; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
Assay: shine high effective liquid chromatography for measuring: chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; The acetonitrile-water of 15:85 ratio is a mobile phase, and the detection wavelength is 230nm, and number of theoretical plate calculates by the peoniflorin peak should be not less than 2600;
The preparation of reference substance solution: precision takes by weighing peoniflorin reference substance 5mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, and promptly gets the reference substance solution that contains peoniflorin 50 μ g among every 1ml;
Need testing solution preparation: get the daily dosage of 0.00072 times in this pharmaceutical composition mixture of embodiment 6 preparations the content uniformity item under, the accurate title, decide, and puts in the tool plug conical flask, precision adds 60% methanol 25ml, and close plug claims to decide weight, power 250W, frequency 40KHZ supersound process 30 minutes is taken out, put coldly, claim again to decide weight, supply minimizing weight with 60% methanol, shake up, get supernatant, filter, promptly;
Algoscopy: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, promptly;
This pharmaceutical composition mixture contains the Radix Paeoniae Alba with peoniflorin C with dosage every day 23H 28O 11Meter should be less than 60mg.
Embodiment 13
Herba Artemisiae Scopariae 960g Radix Isatidis 960g Rhizoma Dryopteris Crassirhizomatis 480g
Poria 960g Radix Curcumae 320g Radix Angelicae Sinensis 480g
The Flos Carthami 320g succinum 96g Radix Paeoniae Alba (stir-fry) 960g
Herba Hedyotidis Diffusae 960g Herba Scutellariae Barbatae 960g Herba Pogostemonis 320g
Herba Eupatorii 480g Fructus Amomi 192g Rhizoma Polygoni Cuspidati 480g
Radix Salviae Miltiorrhizae 960g Herba Lycopi 480g Radix Bupleuri 320g
Rhizoma Paridis 480g
Method for making: above 19 flavors, Radix Angelicae Sinensis, Radix Curcumae, Herba Pogostemonis, Herba Eupatorii, Fructus Amomi, Herba Lycopi extracted volatile oil 8 hours, and the aqueous solution after distillation device is in addition collected, volatile oil 40 ℃ of inclusions of beta-schardinger dextrin-saturated water solution method of 40g, 40 ℃ of dryings get the volatile oil beta-cyclodextrin inclusion complex, and are standby; Radix Salviae Miltiorrhizae is with 85% ethanol 6700ml reflux, extract, secondary, and each 1 hour, merge extractive liquid, filtered, and filtrate recycling ethanol is not to there being the alcohol flavor, Radix Salviae Miltiorrhizae extract, standby; 12 flavors such as medicinal residues and all the other Herba Artemisiae Scopariaes decoct with water secondary, add 8 times of water gagings decocted 1.5 hours at every turn, collecting decoction, filter, the aqueous solution after filtrate and the above-mentioned distillation merges, and being concentrated into relative density is 1.02~1.04 (60~65 ℃), adding ethanol makes and contains alcohol amount and reach 70%, left standstill 24 hours, and filtered, filtrate recycling ethanol is to an amount of, merge with above-mentioned Radix Salviae Miltiorrhizae extract, and be concentrated into the thick paste that relative density is 1.10-1.15 (60~65 ℃), add the volatile oil beta-cyclodextrin inclusion complex and be ground into fine powder, and appropriate amount of auxiliary materials, add water, fill, sterilization, promptly.
[discriminating]
(1) get this product 5g, add water 20ml and make dissolving, with ethyl acetate extraction 2 times, 30ml for the first time, 20ml for the second time, combined ethyl acetate liquid, water bath method, residue add ethyl acetate 1ml makes dissolving, as need testing solution; Other gets Herba Artemisiae Scopariae control medicinal material 1g, adds water 50ml, decocts 1 hour, gets supernatant, is concentrated into 20ml, shines medical material solution with ethyl acetate in pairs with legal system; Draw need testing solution 1 μ l, control medicinal material solution 5 μ l put respectively on same silica gel g thin-layer plate, are developing solvent with petroleum ether (60-90 ℃)-ethyl acetate (1:1), launch, and take out, and dry, and put under the ultra-violet lamp (365nm) and observe; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
(2) get this product 2g porphyrize, add 50% ethanol 15ml, supersound process 20 minutes filters, and filtrate is as need testing solution; Other gets the peoniflorin reference substance, adds ethanol and makes the solution that every 1ml contains 1mg, in contrast product solution; According to thin layer chromatography (" an appendix VI of Chinese pharmacopoeia version in 2005 B) test, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with chloroform-ethyl acetate-methanol-formic acid (40:5:10:0.2) is developing solvent, launch, take out, dry, spray is with 5% vanillin sulfuric acid solution, and 105 ℃ to be heated to the speckle colour developing clear; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
(3) get this product 10g, porphyrize, the 30ml that adds diethyl ether, reflux, extract, 30 minutes filters, and filtrate volatilizes, and residue adds ethyl acetate 0.5ml makes dissolving, as need testing solution; Other gets Radix Angelicae Sinensis control medicinal material 1g, the 10ml that adds diethyl ether, and supersound process 10 minutes filters, and filtrate volatilizes, and residue adds ethyl acetate 1ml makes dissolving, in contrast medical material solution; According to thin layer chromatography (" an appendix VI of Chinese pharmacopoeia version in 2005 B) test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with petroleum ether (60-90 ℃)-ethyl acetate (9.5:0.5) is developing solvent, launch, take out, dry, put under the ultra-violet lamp (365nm) and inspect; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
(4) get the tanshinone reference substance, add ethyl acetate and make the solution that every 1ml contains 2mg, in contrast product solution; According to thin layer chromatography (" appendix VIB of Chinese pharmacopoeia version in 2005) test, draw the need testing solution 10 μ l under the item of [discriminatings] (3), reference substance solution 5 μ l, putting respectively on same silica gel g thin-layer plate, is developing solvent with thiacyclohexane-ethyl acetate (6:1), launches, take out, dry; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical kermesinus speckle.
(5) get this product 5g, porphyrize adds methanol 20ml, supersound process 20 minutes filters the filtrate evaporate to dryness, residue adds 2.5mol/L sulfuric acid solution 10ml makes dissolving, puts in the water-bath and heats 30 minutes, immediately cooling, extract twice with the chloroform jolting, each 10ml merges chloroform liquid, evaporate to dryness, residue adds methanol 1ml makes dissolving, as need testing solution; Other gets the emodin reference substance, adds methanol and makes the solution that every 1ml contains 1mg, in contrast product solution; According to thin layer chromatography (" appendix VIB of Chinese pharmacopoeia version in 2005) test, draw each 6 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, upper solution with petroleum ether (30~60 ℃)-Ethyl formate-formic acid (15:5:1) is developing solvent, launch, take out, dry, put in the ammonia smoked after, inspect under the daylight; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Assay: according to high effective liquid chromatography for measuring
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; Acetonitrile-water (15:85) is a mobile phase, and the detection wavelength is 230nm; Number of theoretical plate calculates by the peoniflorin peak should be not less than 2600;
The preparation precision of reference substance solution takes by weighing peoniflorin reference substance 5mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, and promptly gets (containing peoniflorin 50 μ g among every 1ml);
This product under the content uniformity item is got in the need testing solution preparation, and porphyrize is got 0.25g, and accurate the title decides, and puts in the tool plug conical flask, and precision adds 60% methanol 25ml, and close plug claims to decide weight, supersound process (power 250W, frequency 40KH Z) 30 minutes, take out, put coldly, claim again to decide weight, supply minimizing weight with 60% methanol; Shake up, get supernatant, filter, promptly;
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure, promptly; The every 1ml of this product contains the Radix Paeoniae Alba with peoniflorin (C 23H 28O 11) meter, must not be less than 0.6mg.

Claims (3)

1. pharmaceutical composition for the treatment of viral hepatitis is characterized in that the crude drug of this pharmaceutical composition consists of:
Poria 500-1500 weight portion, Herba Artemisiae Scopariae 500-1500 weight portion, Rhizoma Atractylodis Macrocephalae 500-1500 weight portion, Radix Curcumae 150-450 weight portion, Radix Angelicae Sinensis 250-750 weight portion, succinum 50-150 weight portion, Radix Paeoniae Alba (parched) 500-1500 weight portion, Herba Scutellariae Barbatae 500-1500 weight portion, Fructus Amomi 100-300 weight portion, Rhizoma Polygoni Cuspidati 250-750 weight portion, Radix Salviae Miltiorrhizae 500-1500 weight portion, Herba Lycopi 250-750 weight portion, Radix Bupleuri 150-450 weight portion, Herba Pogostemonis 150-450 weight portion, Herba Eupatorii 250-750 weight portion, Flos Carthami 150-450 weight portion.
2. a kind of pharmaceutical composition for the treatment of viral hepatitis as claimed in claim 1 is characterized in that the crude drug of this pharmaceutical composition consists of:
Poria 960 weight portions, Herba Artemisiae Scopariae 960 weight portions, the Rhizoma Atractylodis Macrocephalae 960 weight portions, Radix Curcumae 320 weight portions, Radix Angelicae Sinensis 480 weight portions, succinum 96 weight portions, Radix Paeoniae Alba (parched) 960 weight portions, Herba Scutellariae Barbatae 960 weight portions, Fructus Amomi 192 weight portions, Rhizoma Polygoni Cuspidati 480 weight portions, Radix Salviae Miltiorrhizae 960 weight portions, Herba Lycopi's 480 weight portions, Radix Bupleuri 320 weight portions, Herba Pogostemonis 320 weight portions, Herba Eupatorii 480 weight portions, Flos Carthami 320 weight portions.
3. as claim 1 or 2 arbitrary described preparation of drug combination methods, it is characterized in that this method is:
Radix Angelicae Sinensis, Radix Curcumae, Herba Pogostemonis, Herba Eupatorii, Fructus Amomi, Herba Lycopi extracted volatile oil 6-10 hour, and the aqueous solution after distillation device is in addition collected; Volatile oil is with the beta-schardinger dextrin-saturated water solution method inclusion of 3-5 times of weight portion, drying, the volatile oil beta-cyclodextrin inclusion complex, standby; Radix Salviae Miltiorrhizae is with 85% alcohol reflux of 4-8 times of weight portion 1-3 time, and each 0.5-1.5 hour, merge extractive liquid, filtered, and filtrate recycling ethanol is not to there being the alcohol flavor, Radix Salviae Miltiorrhizae extract, standby; Medicinal residues and all the other flavour of a drug decoct with water 1-3 time, and the decocting that at every turn adds 6-10 times of weight portion boiled 1-2 hour, and collecting decoction filters; Aqueous solution after filtrate and the above-mentioned distillation merges, be concentrated into 60~65 ℃ of relative densities and be 1.02~1.04 thick paste I, add ethanol and make and contain alcohol amount and reach 60-80%, left standstill 12-36 hour, filter, filtrate recycling ethanol is to an amount of, merge with above-mentioned Radix Salviae Miltiorrhizae extract, and the thick paste II that to be concentrated into 60~65 ℃ of relative densities be 1.10-1.15, add 80% simple syrup 900-1200 parts by volume, the volatile oil beta-cyclodextrin inclusion complex is ground into fine powder, adds in the extractum; Add sodium benzoate 9-10g again, stir evenly, add water to the 3000-4500 parts by volume, filter, fill, sterilization, promptly.
CN 200710119920 2007-08-03 2007-08-03 Medicine combination for treating viral hepatitis and quality control method thereof Active CN101357215B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200710119920 CN101357215B (en) 2007-08-03 2007-08-03 Medicine combination for treating viral hepatitis and quality control method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200710119920 CN101357215B (en) 2007-08-03 2007-08-03 Medicine combination for treating viral hepatitis and quality control method thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201210424453.8A Division CN102967662B (en) 2007-08-03 2007-08-03 Detection method for pharmaceutical composition for treating viral hepatitis
CN 201110033498 Division CN102091299B (en) 2007-08-03 2007-08-03 Method for detecting medicinal composition for treating viral hepatitis

Publications (2)

Publication Number Publication Date
CN101357215A CN101357215A (en) 2009-02-04
CN101357215B true CN101357215B (en) 2011-03-30

Family

ID=40329901

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200710119920 Active CN101357215B (en) 2007-08-03 2007-08-03 Medicine combination for treating viral hepatitis and quality control method thereof

Country Status (1)

Country Link
CN (1) CN101357215B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104491714A (en) * 2014-12-10 2015-04-08 黄平县兴且民族民间中草医药科学发展有限责任公司 Traditional Chinese medicine preparation for treating acute viral hepatitis
CN105987981B (en) * 2015-02-28 2018-04-13 九芝堂股份有限公司 A kind of detection method of oriental wormwood inclusion compound
CN110426487B (en) * 2019-08-05 2021-06-01 浙江金大康动物保健品有限公司 Multi-information rapid thin-layer identification method for rhizoma dryopteris crassirhizomae medicinal material
CN113325115A (en) * 2021-07-08 2021-08-31 辽宁华润本溪三药有限公司 Method for establishing characteristic spectrum of qi stagnation stomachache granules and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1421234A (en) * 2002-12-13 2003-06-04 郭言勋 Oral liquid for treating hepatitis B

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1421234A (en) * 2002-12-13 2003-06-04 郭言勋 Oral liquid for treating hepatitis B

Also Published As

Publication number Publication date
CN101357215A (en) 2009-02-04

Similar Documents

Publication Publication Date Title
CN101850070B (en) Detection method for Chinese medicament Tangcao tablets
CN101574486A (en) Quality control method for Chinese medicinal capsule for treating anemofrigid cold
CN100402053C (en) Method for quality control of traditional Chinese medicine prepns.
CN102579860B (en) Child medicament extract composition and preparation method and application thereof
CN101513519B (en) Chinese medicinal composition for invigorating Qi and nourishing blood, preparation method and quality control method thereof
CN1806846A (en) Chinese medicinal composition, its preparation process and quality control method
CN101856449B (en) Chinese medicinal composition for clearing heat and promoting diuresis, activating blood and treating stranguria, preparation method and quality detection method
CN100418563C (en) Quality control method of Chinese medicinal preparation
CN101396544A (en) Traditional Chinese medicine composition capable of ventilating the lung and relieving asthma and preparation and quality control method thereof
CN101357215B (en) Medicine combination for treating viral hepatitis and quality control method thereof
CN101496870B (en) Chinese medicinal composition for resolving phlegm and suppressing cough as well as preparation method and quality control method thereof
CN102335402A (en) Detection method of Chinese preparation mixture for invigorating the spleen and replenishing qi
CN101422595B (en) Traditional Chinese medicine composition for treating dizziness and preparation method and quality control method thereof
CN101011527B (en) Improved preparation of Juhong pill, its preparation method and quality inspection method
CN101953915A (en) Content measuring method and discriminating method for pharmaceutical composition preparation
CN104306500A (en) Method for detecting medicine for treating irritable bowel syndrome
CN101229323B (en) Lily oral liquid and quality standard and test method of pharmaceutical preparation thereof
CN102091299B (en) Method for detecting medicinal composition for treating viral hepatitis
CN102861255B (en) A kind ofly treat the medicine of influenza and the preparation method of preparation thereof and method of quality control
CN106370756A (en) Detection method of traditional Chinese medicine preparation for preventing infectious bronchitis
CN102218122A (en) Quality control and detection method for sea dragon and gecko oral liquid
CN101011474B (en) Limitary determination of traditional medicine aconitine containing radix aconiti kusnezoffii praeparata
CN102967662B (en) Detection method for pharmaceutical composition for treating viral hepatitis
CN1857445B (en) Quality control method for Desheng preparation
CN101879271B (en) Quality detection method of red tangerine peel capsule

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant